Germany, Berlin-based synthetic biology startup Cambrium has raised €8 million in a seed funding round led by Essential Capital, alongside SNR, Valor Equity Partners, and HOF Capital. Cambrium, led by CEO Mitchell Duffy, aims to leverage the funding to expand its manufacturing and commercial activities, specifically for NovaColl™, as it scales toward replacing traditional animal-derived collagen. The investment will also accelerate the development of Cambrium's product pipeline, introducing new molecules for various applications and industries in the next two years. With this round, Cambrium's total funding reaches €11 million, including previous investment from Merantix.